Home > Cardiology > No difference in net adverse clinical events with clopidogrel, ticagrelor after PCI

No difference in net adverse clinical events with clopidogrel, ticagrelor after PCI


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
JAMA
Reuters Health - 27/10/2020 - Net adverse clinical events (NACE) in the 12 months following percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) do not differ significantly between patients taking ticagrelor or clopidogrel, according to a new study. "In our observational study, ticagrelor use was not associated with reduced ischemic risk, but it was associated with increased hemorrhagic risk (compared with) clopidogrel use," Dr. Seng Chan You of Ajou University School of Medicine, in Suwon, South Korea, told Reuters Health by email. "Current (American College of Cardiology/American Heart Association) guidelines recommend ticagrelor over clopidogrel or prasugrel based on the single pivotal sponsor-initiated trial, PLATO, which was published a decade ago (2009)," he explained. "Our study raised doubts about the current guideline." For their study, Dr. You and colleagues used data from two electronic-health-record databases in the United St...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on